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Knockout miceSeveral reports have recently demonstrated a detrimental role of Toll-like receptors (TLR) in cerebral
ischemia, while there is little information about the endogenous ligands which activate TLR-signaling. The
myeloid related proteins-8 and-14 (Mrp8/S100A8; Mrp14/S100A9) have recently been characterized as
endogenous TLR4-agonists, and thus may mediate TLR-activation in cerebral ischemia. Interestingly, not only
TLR-mRNAs, but also Mrp8 and Mrp14 mRNA were found to be induced in mouse brain between 3 and 48 h
after transient 1 h focal cerebral ischemia/reperfusion. Mrp-protein was expressed in the ischemic
hemisphere, and co-labeled with CD11b-positive cells. To test the hypothesis that Mrp-signaling contributes
to the postischemic brain damage, we subjected Mrp14-deﬁcient mice, which also lack Mrp8 protein
expression, to focal cerebral ischemia. Mrp14-deﬁcient mice had signiﬁcantly smaller lesion volumes when
compared to wild-type littermates (130±16 mm3 vs. 105±28 mm3) at 2 days after transient focal cerebral
ischemia (1 h), less brain swelling, and a reduced macrophage/microglia cell count in the ischemic
hemisphere. We conclude that upregulation and signaling of Mrp-8 and-14 contribute to neuroinﬂammation
and the progression of ischemic damage.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
After focal cerebral ischemia, primary brain damage results from a
complex pattern of pathophysiological events including exitotoxicity,
peri-infarct depolarizations, inﬂammation, and apoptosis [1-5].
Recent expression analysis revealed that Toll-like receptors (TLR)
TLR-2, -4, and-9 are induced in postischemic brain tissue [6]. Toll-like
receptors (TLRs) represent a family of pattern-recognition trans-
membrane receptors which are able to recognize a large number of
conserved structural motifs, called pathogen-associated molecular
patterns (PAMPs). While TLRs have a crucial role in the innate
immune response to invading pathogens and infection, recent
ﬁndings also suggest an important role in neurodegenerative
disorders: TLRs are thought to be activated by endogenous ‘danger
signals’ released from injured or necrotic cells and contribute to the
initiation of the inﬂammatory response as well as apoptotic cell
death [3,5,7-15]. TLR2 and TLR4 were recently shown to mediate
ischemic brain damage in mice, potentially by activating pro-iversitätsmedizin Berlin; CCM,
450 560024; fax: +49 30 450
. Trendelenburg).
ll rights reserved.apoptotic pathways and the release of proinﬂammatory cytokines
[3,4,6,16-22].
Until now, it is not known which ligands activate TLR-signaling in
cerebral ischemia. Molecules such as monosodium urate, hyalur-
onan, heat shock proteins, or high mobility group box protein 1
(Hmgb1) were shown to activate TLR-signaling and thus may
potentially act as endogenous TLR-ligands in postischemic brain
damage [5,18,23].
Very recently, myeloid related protein 8 (Mrp8) and Mrp14 (also
called Calgranulin A and Calgranulin B or S-100 calcium binding
protein A8 [S100A8] or S100 calcium binding protein A9 [S100A9],
respectively) were characterized as endogenous Toll-like receptor-4
(Tlr-4) agonists [24]. Mrp8/S100A8 and Mrp14/S100A9, as well as
S100A6 (Calcyclin) belong to the S100 protein family and are
expressed in activated macrophages and microglial cells [25,26].
S100-family members are characterized by the presence of two
calcium binding sites, the so-called EF-hands, which modulate cell-
speciﬁc functions and interactions, such as vesicle production and
phagocytosis, activation and gene regulation, cell differentiation, and
proliferation [25]. Calprotectin, the complex of Mrp8/S100A8 and
Mrp14/S100A9, is a major calcium- and zinc-binding protein of
phagocytotic cells of myeloid origin and both proteins comprise about
40% of the cytosolic protein of neutrophils [27].
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postischemic brain damage by activating pro-inﬂammatory signaling
pathways. Whereas Mrp8-deﬁciency causes early resorption of the
mouse embryo [26], Mrp14-deﬁcient mice, which are viable, do not
express Mrp8 in the adult mice, thus allowing the functional analysis
of Mrp-8 and-14 in adult mice after stroke [27,28]. Thus, we tested
whether Mrp14-deﬁcient mice were protected against cerebral
ischemia and whether they have a reduced inﬂammatory response.
Since Mrp-deﬁcient mice were signiﬁcantly protected in our study
and have reducedmacrophage/microglia cell count in amurine stroke
model when compared to wild-type control mice, we conclude that
Mrp8/14 contributes to postischemic tissue damage, potentially by
promoting neuroinﬂammation via Tlr4-signaling.
2. Materials and methods
2.1. Animals
Adult 9–13 weeks old male Mrp14−/− mice [28] were provided
by Dr. W. Nacken (Department of Experimental Dermatology,
University of Münster, Germany). Targeted deletion of Mrp14 results
in a loss of both the Mrp8 and the Mrp14 proteins in mice [24,27,28].
The Mrp14−/− mice had been backcrossed to the original C57Bl/6J
background for more than 10 generations. Age matched male 9–
14 week old C57Bl/6J littermates were used as control in all
experiments. The body weight of Mrp14+/+ control mice (C57Bl/
6J littermates)was23.7±2.7 g compared to 24.0±2.0g inMrp14−/−
mice. All animal handling and surgery were performed in accordance
with the Guidelines for the Use of Animals in Neuroscience Research
(Society forNeuroscience). All experimentswere approved by the local
institutional Animal Care Committee, LAGeSo (No.G0382/05). Mice
were housed under diurnal lighting conditions and allowed access to
food and water ad libitum. All experiments were performed in a
randomized manner, and surgery, as well as infarct volume determi-
nation was performed by investigators blinded to the groups.
2.2. Induction of focal cerebral ischemia
Middle cerebral artery occlusion (MCAO)was induced by inserting
a silicone-coated ﬁlament (Xantopren M Mucosa and Activator NF
Optosil Xantopren, Heraeus Kulzer, Wehrheim, Germany) via the
internal carotid artery as described by Gertz et al. [29]. For sham
control, the operationwas performedwithout advancing the ﬁlament.
Mice were anaesthetized with 2% isoﬂurane for induction and
maintained with 1.5% isoﬂurane 70% N2O and 30% O2 via a face
mask. Anesthesia did not exceed 10 min. After 60 min, the animals
were re-anaesthetized for 1 min and the ﬁlament was removed to
permit reperfusion. In all animals during surgery and ischemia, body
temperature was measured and maintained between 37.0 and 37.5 °C
with a heating pad.
2.3. Analysis of gene expression
Mice were deeply anaesthetized and decapitated at speciﬁed time
points of reperfusion. The brains were removed rapidly from the skull.
RNA derived from ipsilateral (ischemic) hemispheres, pooled from 6
wild-type C57Bl/6mice (after MCAO, respectively sham treatment) at
each time point was used for Affymetrix GeneChip experiments using
Affymetrix GeneChip Mouse Expression Set 430 (Affymetrix, Santa
Clara, CA). For Illumina Sentrix arrays (Illumina, San Diego, CA), ipsi-
and contralateral hemispheres of MPR14-deﬁcient and C57Bl/6 wild-
type mice were pooled from three animals each group and time point.
The RNA was isolated with Trizol Reagent (Invitrogen, Karlsruhe,
Germany) and was transcribed into cDNA (SuperScript II; Invitrogen,
Karlsruhe, Germany). In order to determine the induction of speciﬁc
mRNAs in the ipsilateral hemispheres of MCAO-treated animals,expression values were compared to those derivated from the
uninjured (contralateral) hemisphere of these animals, as well as to
those derived from sham-operated animals. Thus, mRNAs of the
contralateral hemispheres of MCAO treated mice, as well as mRNAs
from the ipsilateral brain hemispheres of sham-treatedwild-typemice
(C57BL/6) were used as a reference for the determination of the
induction of mRNAs derived from the ipsilateral brain hemisphere of
MCAO-treated mice. Commercially available Affymetrix software as
well as Beadstudio (Illumina, San Diego, CA) was applied for data
analysis of Affymetrix GeneChips and Illumina Sentrix array, respective-
ly. Fold change (FC) was calculated using the following formula:
FC=2m, form ≥ 0, and FC=(−1)×2−m formb0, withm=log2ratio.
Mrp8/S100A8 expression was assessed by the probe 1419394_at
(Affymetrix-ID) and scl22940.2.1_25-S (Illumina-ID), Mrp14/S100A9
by probe 1448756_at (Affymetrix-ID) and scl020202.1_47-S (Illu-
mina-ID), and S100A6/Calcyclin by probe 1421375_a_a (Affymetrix-
ID) and scl22942.3.1_64-S (Illumina-ID), respectively.
2.4. Assessment of infarct volume
At 48 h after the induction of ischemia for 60min,micewere deeply
anaesthetized and scariﬁed; the brainswere removed rapidly from the
skull and snap frozen in 2-methylbutane on dry ice. Brains were
sectioned (12 μm) on a microtome, dried overnight, and stained with
hematoxylin (Merck, Darmstadt, Germany). The sections were
digitized, the area of infarction was quantiﬁed on a PC using Sigma
Scan Pro Software (Jandel Scientiﬁc, San Rafael, CA), and infarct
volumes were calculated. The ‘indirect’ infarct volume was calculated
as the volume of the contralateral hemisphere minus the non-
infarcted volume of the ipsilateral hemisphere. The difference
between ‘direct’ and ‘indirect’ infarct volumes represents brain
swelling [30]. Therewas no need to exclude animals due to insufﬁcient
occlusion of themiddle cerebral artery, because therewere no animals
without an infarct in both groups (MRP14−/− and MRP14+/+).
2.5. Quantiﬁcation of inﬂammatory cells in the ischemic hemisphere
The number of cd11b-positive cells was determined by counting
all cd11b-positive cells at interaural position No. III (distance to
bregma 3.9 mm) in the whole ischemic hemisphere of mice at 48 h
after induction of cerebral ischemia (MCAO) for 60 min.
2.6. Statistical analysis
Student's t-test for independent samples was applied to determine
statistical signiﬁcance between themean values of two study groups if
not stated otherwise. p-values below 0.05 were considered statisti-
cally signiﬁcant. If groups were not normal distributed, Mann-
Whitney-U-test was used (comparison of infarct volumes and
cd11b-positive cells). As not stated otherwise, values are given as
mean value±standard deviation (SD).
2.7. Immunohistochemistry
Staining was performed on fresh frozen tissue harvested at 48 h of
reperfusion. From the fresh frozen tissue, 12 μm coronar cryosections
at interaural positions 6.6, 5.3, 3.9, 1.9, and 0mmwere thaw-mounted
onto glass slides. Slides were air-dried for 30 min and ﬁxed for 5 min
in−20 °C methanol and acetone (1:1), dried for 15 min, and washed
in PBS for 5 min. Next, the sections were incubated in blocking
solution containing 3 % normal goat serum and 0.3 % Triton X-100
(Sigma) in PBS for 60min. The slides were incubated over night at 4 °C
with a polyclonal rabbit anti-Mrp14/S100A9 antibody (gift from W.
Nacken, Münster, Germany) [24] at a dilution of 1:300. For the
detection of primary antibody, slides were incubated with Alexa488
conjugated goat anti-rabbit IgG (Invitrogen) at 1:200 for 1 h at room
Table 1
Expression of S100-family genes in ischemic mouse brain.
Gene symbol Accession number FC 1 h FC 3 h FC 6 h FC 12 h FC 24 h
S100A5 1449927_at n.d. −1.71 n.d. −1.11 2.22
S100A6 1421375_a_a 1.41 1.47 1.15 2.81 3.46
S100A8 1419394_s_a n.d. −1.51 1.19 4.32 3.81
S100A9 1448756_at n.d. −1.46 −1.20 1.99 1.97
S100A10 1416762_at −1.23 −1.25 1.02 1.70 1.79
S100A13 1418704_at −1.43 1.21 1.54 1.80 1.72
mRNA expression level was measured after extracting RNA from whole ischemic hemispheres (n=6), at various time points of reperfusion after 1 h MCAO by using Affymetrix
GeneChip Mouse Expression Set 430 (Affymetrix, Santa Clara, CA). Expression ratio was calculated by the use of the ratio of the signal intensity in the ipsilateral/ischemic hemisphere
and the signal of the non-ischemic hemisphere of sham-operated animals of the same wild-type strain (C57Bl6). The regulation of different S100-family genes is displayed as fold
change (FC), downregulation is indicated by ‘−’ .
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additional staining of endothelial cells was performed using rat
anti-CD31 (550274; BD Pharmingen, San Jose, CA, USA), while rat
anti-CD11b (Santa Cruz Biotechnology inc., CA) was used at 1:200 to
stain macrophages/microglia. Secondary antibodies were obtained
commercially from Jackson ImmunoResearch (West Grove, PA).
3. Results
3.1. Mrp8 and Mrp14 mRNA are induced after focal cerebral ischemia in
the mouse
Expression values for S100A family members were determined
using Affymetrix GeneChip arrays (Set 430) in combination with
transcripts pooled from six ipsilateral mouse brain hemispheres at the
time points 1, 3, 6, 12, and 24 h of reperfusion after 1 h of middle
cerebral artery occlusion and compared to sham treated mice. Nearly
2000 genes out of more than 39,000 mRNA transcripts were
upregulated signiﬁcantly at least twofold with a p-value below 0.05
(data not shown). Several induced genes are related to inﬂammation
or apoptosis (KEGG Pathway Database; BioCarta Charting Pathways of
Life), including Mrp8/S100A8 and Mrp14/S100A9 (Table 1). The Af-
fymetrix GeneChip results revealed a signiﬁcant upregulation of Mrp8Fig. 1. Mrp14 protein is induced in the ischemic mouse brain. Mouse brain tissue 48 h after
Mrp14-positive cells are almost exclusively observed in the ipsilateral (ischemic) hemisphere
of the ischemic tissue, but are not found in the contralateral (non-ischemic) hemisphere (A). P
peri-infarct region (B) of the ischemic hemisphere. (C, D) Hoechst 33258 staining of the celas well as Mrp14 mRNA during the ﬁrst day of reperfusion, reaching
the maximal induction at 12 h of reperfusion after induction of
cerebral ischemia when compared to sham treated mice. Moreover,
other members of the S100A-family were also found to be induced in
postischemic brain tissue. After a minor downregulation at very early
time points, induction of most S100A-family members started around
6 to 12 h after the start of reperfusion (Table 1).
Apart from Affymetrix GeneChip analysis, which was performed to
investigate early mRNA expression patterns ‘over time’, gene
expression was also compared between ipsilateral and contralateral
hemispheres (comparison ‘over space’). Gene expression proﬁles
were determined from ipsilateral (as well as contralateral) brain
hemispheres (n=3) at 48 h of reperfusion after 1 h MCAO
(respectively at 72 h after 30 min MCAO) to compare gene-speciﬁc
expression in the ischemic hemisphere not only with the sham-
operated mice as reference (as done for the initial Affymetrix
screening experiment), but also to allow comparison between ipsi-
and contralateral hemispheres. Upregulation of Mrp8 mRNA (Target
ID: scl22940.2.1_25-S; Illumina Sentix arrays), as well as Mrp14
mRNA (Target ID: scl020202.1_47-S; Illumina Sentix arrays) was
conﬁrmed by Illumina Sentix arrays in the ipsilateral hemisphere at
48 h, but already declines at 72 h after the induction of the ischemia
(data not shown).1 h MCAO was stained with polyclonal rabbit anti-Mrp14 antibody (Vogl et al. 2007).
. They are scattered around the peri-infarct border zone (B) and partially also in the core
anel A is derived from a region of the contralateral hemispherewhich corresponds to the
l nuclei in the regions shown in panels A and B, respectively. Scale bar = 80 μm.
Fig. 2. Identiﬁcation of Mrp14 expressing cells in the ischemic brain tissue. Double staining of ischemic mouse brain tissue 48 h after 1 h MCAO in the ischemic hemisphere.
Immunohistochemical staining of Mrp14 (ﬁrst column), and cell-speciﬁc marker (second column) for endothelial cells (Cd31), respectively, invading macrophages/microglial cells
(Cd11b). Cell nuclei were stained using Hoechst 33258 stain, which stains DNA. The merge of the three different stainings is displayed in the forth column (overlay). Mrp14-positive
cells were identiﬁed as invading macrophages/activated microglia, and are found mainly in the peri-infarct region of the ischemic hemisphere. Cells localized in the ischemic tissue
were also found around vessels as exempliﬁed in the right upper image (Mrp14/Hoechst/Cd31-overlay). Scale bar = 50 μm.
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mouse brain
The induction of Mrp14 protein in postischemic brain tissue was
conﬁrmed by immunohistochemistry at 48 h of reperfusion after
1 h MCAO. Mrp14 protein expression was not detected in the non-
ischemic, contralateral hemisphere. By contrast, a strong upregula-
tion was found in the ipsilateral hemisphere with highest
expression in the peri-infarct region (Fig. 1) and lower signal
density in the infarct core. Double labeling (Fig. 2) identiﬁed the
Mrp14-immunopositive cells as microglia and inﬁltrating myeloid
cells/macrophages. In contrast, Mrp14-positive signals did not
colocalized with endothelial cells or neurons of the ischemic
hemisphere, but were often found in the immediate vicinity of
small vessels (Fig. 2).
Mrp14−/−mice have a smaller direct infarcts and reduced brain
swelling when compared to Mrp14+/+ mice. To test whether the
Mrp14 protein is of functional relevance in cerebral ischemia, infarct
volumes of male Mrp14-deﬁcient mice and littermates after 1 h
MCAO and 2 days of reperfusion were compared: infarct volumes of
Mrp14−/− mice were signiﬁcantly smaller than infarct volumes of
Mrp14+/+ mice (Fig. 3). The mean direct infarct volume of
littermates (Mrp14+/+; n=11) was 24 percent larger than that
observed in Mrp14-deﬁcient mice (n=11) (mean value±standard
deviation: 130 mm3±16 vs. 105 mm3±28; p=0.016) (Fig. 3A).
There was only a tendency without signiﬁcance toward larger indirect
infarct volumes in Mrp14+/+ mice when compared to Mrp14-
deﬁcient mice (mean±SD: 74 mm3±20 vs. 83 mm3±8; p= 0.18)
(Fig. 3B), whereas the calculated brain swelling was signiﬁcantly
larger in Mrp14+/+ mice when compared to Mrp14-knockout mice
(mean±SD: 47 mm3±13 vs. 31 mm3±13; p= 0.005) (Fig. 3C).
3.3. Mrp-8 and -14 contribute to the inﬂammatory response in
postischemic brain tissue
There were signiﬁcantly less Cd11b-positive cells (macrophages/
activated microglia) found in the ischemic hemisphere at 48 h of
reperfusion in Mrp14-deﬁcient mice (727±124; Pt-test= 0.003),
when compared to Mrp14+/+ wild-type littermates (1107±136)
(Fig. 4A). Moreover, visualization of inﬂammatory cell numbers and
infarct volumes revealed that Mrp14+/+ mice have an increasedinﬂammatory cell count when compared to Mrp14-deﬁcient mice, an
observation which is also true for animals with similar infarct sizes
(Fig. 4B).
4. Discussion
This study has the following major ﬁndings: (1) S100A genes
(including Mrp8 and Mrp14) are signiﬁcantly induced in cerebral
ischemia; (2) Mrp14-deﬁciency decreases brain swelling and the
direct infarct volume at 48 h of reperfusion; and (3) Mrp14-deﬁcient
mice have a reduced inﬂammatory cell count in postischemic brain
tissue.
MRP8- and MRP14-positive cells were detected in various brain
pathologies, including Alzheimer's plaques, multiple sclerosis lesions,
experimental allergic encephalomyelitis, cerebral malaria, and trau-
matic brain lesions [25,31]. Ischemic human brains showed ramiﬁed
microglial cells expressing both Mrp8 and Mrp14 in the ﬁrst 3 days
after insult in the peri-infarctional area [32,33]. Furthermore, theMrp8
transcript was upregulated by oxidative stress such as ultraviolet A
irradiation and H2O2 [34]. Thus, our current data, which demonstrate
an induction of Mrp8 and Mrp14 as well as of other S100A-family
members in cerebral ischemia, are in good agreement with previous
reports.
Some members of the S100-protein family, such as Mrp8 and
Mrp14, are secreted from cells upon stimulation, exerting cytokine-
and chemokine-like extracellular activities [35]. Mrp8 and -14 were
shown to impair endothelial integrity, cause endothelial damage, and
Mrp8 is one of the most potent chemotactic factors described [36,37].
Accordingly, release of the heterodimer Mrp8/14 (S100A8/A9)
substantially ampliﬁes neutrophil recruitment in gouty inﬂammation
[38,39], and high concentrations of calprotectin (complex of Mrp8 and
Mrp14) in humans result in a syndrome with recurrent infections,
inﬂammation, and hyperzincemia [40]. Thus, our observation of a
reduced infarct volume in Mrp14-deﬁcient mice could be explained
by a reduced inﬂammation, which was demonstrated by a reduced
brain swelling (Fig. 3C) and a reduced inﬂammatory cell number in
the ischemic hemisphere (Fig. 4). The observation that leukocyte
inﬁltration between Mrp14-deﬁcient and wild-type littermates
signiﬁcantly differs also in those mice that do not have signiﬁcant
differences in lesion size argues against a simple secondary effect due
to different infarct volumes.
Fig. 3. Comparisonof infarctvolumesofMrp14-/-andwild-type littermates (Mrp14+/+).
Direct infarct volume after 1 h induction of cerebral ischemia at 2 days of reperfusion
is signiﬁcantly (p= 0.016) smaller in Mrp14-knockout mice (Mrp14−/−) (n=11)
when compared to wild-type littermates (Mrp14+/+) (n=11) (Fig. 3A). Infarct
volume is visualized as box-and-whisker plots. Statistical analysis was performed
using the Mann–Whitney U-test. In contrast to the signiﬁcant differences of the direct
infarct volumes (Fig. 3A) and the calculated edema (p= 0.005) (Fig. 3C), there was
only a tendency without statistical signiﬁcance of the indirect infarct volume (Fig. 3B).
Indirect infarct volumes were calculated as the volume of the contralateral
hemispheres minus the non-infarcted volumes of the ipsilateral hemispheres. Brain
swelling was calculated as the direct minus the indirect infarct volumes. In all box
plots, the top of the box represents the 75th percentile, the bottom of the box
represents the 25th percentile, and the line in the middle represents the 50th
percentile. The whiskers (the lines that extend out the top and bottom of the box)
represent the highest and lowest values that are not outliers or extreme values.
Outliers (values that are between 1.5 and 3 times the interquartile range) and extreme
values (values that are more than 3 times the interquartile range) are represented by
points.
Fig. 4. Comparison of inﬂammatory cell count in the ischemic hemisphere ofMrp14−/−
and wild-type littermates (Mrp14+/+). The number of cd11b-positive cells was
determined by counting all cd11b-positive cells at interaural position No. III (distance
to bregma 3.9 mm) in the whole ischemic hemisphere of Mrp14-deﬁcient, as well as
Mrp14+/+ control mice at 48 h after induction of cerebral ischemia (MCAO) for
60 min. There are signiﬁcant (p= 0.003) less inﬁltrating macrophages/microglia in the
ischemic hemisphere of Mrp14-deﬁcient mice when compared to the ischemic
hemisphere of wild-type littermates (Mrp14+/+) (n=4, respectively n=5) (A).
Whole cell counts in the ipsilateral hemispheres are visualized as box-and-whisker
plots. (B) Correlation between inﬂammatory cell counts (number of cd11b-positive
cells in the ischemic hemisphere in Mrp14-deﬁcient and Mrp14+/+ mice/wild-type
littermates) and indirect infarct sizes.
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endogenous activators of Toll-like receptor-4 signaling, which
promotes lethal, endotoxin-induced shock. Thus, our data, which
demonstrate that Mrp8/Mrp14 signiﬁcantly contribute to ischemicbrain injury and inﬂammation, are in good agreement with recent
data, which demonstrate that TLR4 contributes to neuroinﬂammation
and to ischemic brain injury [9,18,19], whereas mild stimulation of
TLR-signaling is able to induce preconditioning effects [41,42].
However, because Mrp14 not only activates TLR4, but also the
receptor for advanced glycation end products (RAGE) [35], it cannot
be excluded that further receptors besides TLR4 may be involved in
Mrp8/14-mediated postischemic damage.
Whether the deleterious effect of Mrp14 observed in our study is
due to a systemic effect (e.g. by invading leukocytes) or due to a
central nervous system effect of Mrp14 signaling remains yet to be
investigated. This could be achieved by the use of cell- or tissue-
speciﬁc (chimeric) Mrp14 knockout mice. Moreover, the contribution
of other S100A genes (Table 1) in postischemic brain injury deserves
further studies, as well as the question if the difference of infarct
volumes at 48 h of reperfusion also persists at later time points (at
which edema will be largely resolved).
The Toll-like receptor 4 (TLR4) is expressed mainly by microglia
and is thought to mediate microglial activation and expression of pro-
inﬂammatory mediators in a response to a variety of ligands [4].
Accordingly, the exacerbation of damage after stroke caused by prior
immobilization stress (which triggers systemic and brain inﬂamma-
1203G. Ziegler et al. / Biochimica et Biophysica Acta 1792 (2009) 1198–1204tion) was attenuated in TLR-4 mutant mice [4,16]. TLR4 signaling
results in NF-κb formation and therefore in transcription of proin-
ﬂammatory signals, such as TNF-alpha and Il-1β, that activate the
innate immune system [3,7,11,43,44].
Besides Mrp8/14, other endogenous TLR4-agonists such as
hyaluronan [23] or Hmgb1 (high mobility group box protein 1) [45],
heat shock proteins and monosodium urate represent further
endogenous ‘danger signals’ [14], which are released by necrotic
cells, and which lead to the initiation of the inﬂammatory immune
response [8,22,38,45,46]. However, since our study does not prove a
causal relationship between the neuroprotective effect of MRP14-
deﬁciency and the hypothesized MRP8/14-mediated TLR4-signaling,
further studies need to be performed, e.g. by the use of MRP14/TLR4-
double knockout mice.
To summarize, we herewith demonstrate an upregulation of
S100A-family members, including Mrp8 and Mrp14 after ischemic
brain injury. Furthermore, we observed a signiﬁcant exacerbation of
brain damage and inﬂammatory cell inﬁltration in wild-type
littermates mice when compared to Mrp-knockout mice, suggesting
a detrimental and pro-inﬂammatory effect of Mrp8/14-mediated
signaling in murine focal experimental stroke.
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